Spots Global Cancer Trial Database for adult glioblastoma
Every month we try and update this database with for adult glioblastoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Pazopanib in Treating Patients With Recurrent Glioblastoma | NCT00459381 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Recurrent Adult... | pazopanib hydro... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma | NCT00516282 | Brain and Centr... | CLORETAZINE temozolomide | 18 Years - | Northwestern University | |
Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain | NCT00039572 | Brain and Centr... Melanoma (Skin) Metastatic Canc... | boronophenylala... | 18 Years - | National Cancer Institute (NCI) | |
Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00482677 | Brain and Centr... | temozolomide DNA methylation... quality-of-life... Radiation | 65 Years - 120 Years | Canadian Cancer Trials Group | |
Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma | NCT01753713 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Recurrent Adult... | dovitinib laboratory biom... | 18 Years - | Case Comprehensive Cancer Center | |
Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma | NCT00423735 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Recurrent Adult... | Dasatinib Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00770471 | Brain and Centr... | temozolomide veliparib DNA methylation... gene expression... mutation analys... proteomic profi... high performanc... immunoenzyme te... laboratory biom... mass spectromet... pharmacogenomic... pharmacological... adjuvant therap... radiation thera... | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00099125 | Brain and Centr... | irinotecan hydr... temozolomide adjuvant therap... radiation thera... | 18 Years - | Radiation Therapy Oncology Group | |
Bispecific Antibody Plus White Blood Cells in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme | NCT00005813 | Brain and Centr... | bispecific anti... lymphokine-acti... conventional su... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
Suramin in Treating Patients With Recurrent Primary Brain Tumors | NCT00002639 | Brain and Centr... | chemotherapy suramin | 15 Years - | National Cancer Institute (NCI) | |
Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma | NCT00005951 | Brain and Centr... | irinotecan hydr... temozolomide | 18 Years - | Duke University | |
Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00047294 | Brain and Centr... | celecoxib temozolomide thalidomide adjuvant therap... | 18 Years - 120 Years | Dana-Farber Cancer Institute | |
Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00047294 | Brain and Centr... | celecoxib temozolomide thalidomide adjuvant therap... | 18 Years - 120 Years | Dana-Farber Cancer Institute | |
Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma | NCT01103375 | Adult Anaplasti... Adult Anaplasti... Adult Diffuse A... Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Adult Mixed Gli... Adult Oligodend... Recurrent Adult... | erlotinib hydro... isotretinoin laboratory biom... protein express... | 18 Years - | Wake Forest University Health Sciences | |
Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | NCT00662506 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... | Cediranib Malea... Diffusion Tenso... Diffusion Weigh... Dynamic Contras... Fludeoxyglucose... Intensity-Modul... Laboratory Biom... Perfusion Magne... Positron Emissi... Temozolomide | 18 Years - | National Cancer Institute (NCI) | |
Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors | NCT00008086 | Brain and Centr... Unspecified Adu... | calcitriol carboplatin | 18 Years - | University of Pittsburgh | |
Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme | NCT00003456 | Glioblastoma Mu... | Antineoplaston ... | 18 Years - 99 Years | Burzynski Research Institute | |
Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma | NCT01310868 | Glioblastoma | 5-ALA Gliadel wafers Radiotherapy as... Concomitant che... Adjuvant chemot... | 18 Years - | University College, London | |
Temozolomide in Treating Patients With Recurrent High-Grade Glioma | NCT00619112 | Recurrent Centr... | temozolomide | 18 Years - | University of California, San Francisco | |
Bevacizumab and Lomustine for Recurrent GBM | NCT01290939 | Glioblastoma Mu... Cognition Disor... Disability Eval... | bevacizumab lomustine DNA methylation... laboratory biom... cognitive asses... quality-of-life... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
Temozolomide Plus Carboplatin in Treating Patients With Recurrent Glioblastoma Multiforme | NCT00021307 | Brain and Centr... | carboplatin temozolomide | 18 Years - | Fox Chase Cancer Center | |
Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors | NCT00039494 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... | erlotinib hydro... 3-dimensional c... temozolomide | 18 Years - | National Cancer Institute (NCI) | |
Feasibility of Individualized Therapy for Recurrent Glioblastoma | NCT03681028 | Recurrent Gliob... | Individualized ... | 18 Years - | University of California, San Francisco | |
Bispecific Antibody Plus White Blood Cells in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme | NCT00005813 | Brain and Centr... | bispecific anti... lymphokine-acti... conventional su... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme | NCT00895180 | Adult Glioblast... | olaratumab ramucirumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00274833 | CNS Tumor, Adul... | erlotinib hydro... temozolomide radiation thera... | 18 Years - | Case Comprehensive Cancer Center | |
Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors | NCT00002647 | Brain and Centr... Metastatic Canc... | verteporfin conventional su... | 3 Years - 70 Years | National Cancer Institute (NCI) | |
Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma | NCT00036972 | Brain and Centr... | cintredekin bes... adjuvant therap... conventional su... neoadjuvant the... | 18 Years - | National Cancer Institute (NCI) | |
AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme | NCT00107237 | Brain and Centr... | AEE788 everolimus | 18 Years - | Novartis | |
Bevacizumab and Lomustine for Recurrent GBM | NCT01290939 | Glioblastoma Mu... Cognition Disor... Disability Eval... | bevacizumab lomustine DNA methylation... laboratory biom... cognitive asses... quality-of-life... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme | NCT00004262 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... | conventional su... 3-dimensional c... stereotactic ra... motexafin gadol... magnetic resona... spectroscopy | 18 Years - | National Cancer Institute (NCI) | |
Motexafin Gadolinium Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00003409 | Brain and Centr... | motexafin gadol... radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00014170 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... | gefitinib pharmacological... laboratory biom... questionnaire a... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma | NCT00008008 | Brain and Centr... | filgrastim sargramostim cyclophosphamid... thiotepa autologous bone... bone marrow abl... peripheral bloo... | - | National Cancer Institute (NCI) | |
Sirolimus in Treating Patients With Glioblastoma Multiforme | NCT00047073 | Brain and Centr... | Rapamycin Surgery Supportive Care | 18 Years - 120 Years | Jonsson Comprehensive Cancer Center | |
AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery | NCT03965494 | Brain and Centr... | BGB 324 (before... BGB 324 (after ... | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
Carboplatin Plus Irinotecan in Treating Patients With Glioblastoma Multiforme | NCT00010036 | Brain and Centr... | carboplatin irinotecan hydr... radiation thera... | 18 Years - | NYU Langone Health | |
Bevacizumab in Recurrent Grade II and III Glioma | NCT01164189 | Central Nervous... | Bevacizumab Temozolomide | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
Vaccine Therapy in Treating Patients With Malignant Glioma | NCT00612001 | Brain and Centr... | glioma-associat... | 18 Years - | Jonsson Comprehensive Cancer Center | |
Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma | NCT01342757 | Adult Glioblast... Depression Recurrent Adult... | vorinostat temozolomide magnetic resona... survey administ... | 18 Years - | National Cancer Institute (NCI) | |
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer | NCT00025558 | Brain and Centr... | filgrastim carboplatin temozolomide thiotepa autologous bone... peripheral bloo... | 1 Year - 49 Years | NYU Langone Health | |
Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00486603 | Brain and Centr... | hydroxychloroqu... temozolomide pharmacological... Radiation | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain Tumors | NCT00005083 | Brain and Centr... | conventional su... magnetic resona... magnetic resona... | 18 Years - 55 Years | Jonsson Comprehensive Cancer Center | |
Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT02227901 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... | Tipifarnib External Beam R... Temozolomide Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma | NCT00401024 | Brain and Centr... | imatinib mesyla... pharmacological... conventional su... | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor | NCT00069940 | Brain and Centr... Gastrointestina... Sarcoma | sargramostim telomerase: 540... | 2 Years - | Dana-Farber Cancer Institute | |
GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma | NCT00293423 | Brain and Centr... | HSPPC-96 Standard Surgic... | 18 Years - | University of California, San Francisco | |
Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma | NCT00087061 | Brain and Centr... | gimatecan | 18 Years - | National Cancer Institute (NCI) | |
Procarbazine in Treating Patients With Recurrent Brain Tumor | NCT00004004 | Brain and Centr... | procarbazine hy... | 18 Years - | National Cancer Institute (NCI) | |
Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme | NCT00002545 | Brain and Centr... | carmustine low-LET photon ... | 18 Years - | Radiation Therapy Oncology Group | |
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors | NCT00003461 | Brain and Centr... Metastatic Canc... Neuroblastoma | surgical proced... astatine At 211... | 18 Years - | Duke University | |
ATN-161 and Carboplatin in Treating Patients With Recurrent Malignant Glioma | NCT00352313 | Brain and Centr... | ATN-161 carboplatin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma | NCT01390571 | Brain and Centr... | olaparib temozolomide gene expression... protein express... laboratory biom... pharmacological... diffusion-weigh... dynamic contras... therapeutic con... | 18 Years - | Cancer Research UK | |
Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM | NCT00004146 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... | radiation thera... carboxyamidotri... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
Radiation Therapy Followed by Carmustine in Treating Patients Who Have Supratentorial Glioblastoma Multiforme | NCT00006386 | Brain and Centr... | carmustine radiation thera... stereotactic ra... | - | Radiation Therapy Oncology Group | |
MRI Scans in Evaluating the Effects of Radiation Therapy and Chemotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Glioma | NCT00756106 | Brain and Centr... | temozolomide Imaging biomark... Photon Radiatio... | 18 Years - | Massachusetts General Hospital | |
Carboplatin Plus Irinotecan in Treating Patients With Glioblastoma Multiforme | NCT00010036 | Brain and Centr... | carboplatin irinotecan hydr... radiation thera... | 18 Years - | NYU Langone Health | |
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma | NCT00010049 | Brain and Centr... | imatinib mesyla... | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
Dalteparin and Radiation Therapy in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme | NCT00028678 | Brain and Centr... | dalteparin radiation thera... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy | NCT00436436 | Brain and Centr... | O6-benzylguanin... temozolomide | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor | NCT00070161 | Brain and Centr... Radiation Toxic... | EGb761 donepezil hydro... cognitive asses... | 18 Years - 120 Years | Wake Forest University Health Sciences | |
Bevacizumab and Lomustine for Recurrent GBM | NCT01290939 | Glioblastoma Mu... Cognition Disor... Disability Eval... | bevacizumab lomustine DNA methylation... laboratory biom... cognitive asses... quality-of-life... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery | NCT00814593 | Brain and Centr... | lymphokine-acti... polifeprosan 20... | 18 Years - | Lisata Therapeutics, Inc. | |
Karenitecin in Treating Patients With Recurrent Malignant Glioma | NCT00014521 | Brain and Centr... | karenitecin | 18 Years - | National Cancer Institute (NCI) | |
Acridine Carboxamide in Treating Patients With Recurrent Glioblastoma Multiforme | NCT00004937 | Brain and Centr... | acridine carbox... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | NCT01013285 | Brain and Centr... | bevacizumab temozolomide external beam r... | 18 Years - | Jonsson Comprehensive Cancer Center | |
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma | NCT00006093 | Brain and Centr... | cilengitide | 18 Years - | National Cancer Institute (NCI) | |
Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors | NCT00012038 | Brain and Centr... | irofulven | 18 Years - | National Cancer Institute (NCI) | |
Acridine Carboxamide in Treating Patients With Recurrent Glioblastoma Multiforme | NCT00004937 | Brain and Centr... | acridine carbox... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant Astrocytoma | NCT00003842 | Brain and Centr... | interleukin-4 P... isolated perfus... surgical proced... | 18 Years - | National Cancer Institute (NCI) | |
Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | NCT00305864 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... | 3-Dimensional C... Motexafin Gadol... Temozolomide | 18 Years - | National Cancer Institute (NCI) | |
Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00005856 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... | oxaliplatin pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00390403 | Brain and Centr... | R-(-)-gossypol ... temozolomide gene expression... mutation analys... protein express... laboratory biom... pharmacological... adjuvant therap... radiation thera... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor | NCT00006358 | Brain and Centr... | temozolomide thalidomide | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
Magnetic Resonance Imaging in Determining Extent of Cancer in Patients With Newly Diagnosed Glioma | NCT00005082 | Brain and Centr... | biopsy magnetic resona... | 18 Years - | Jonsson Comprehensive Cancer Center | |
Boron Neutron Capture Therapy Following Surgery in Treating Patients With Glioblastoma Multiforme Removed During Surgery | NCT00004015 | Brain and Centr... | sodium borocapt... adjuvant therap... | 50 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
Carmustine in Treating Patients With Recurrent Malignant Glioma | NCT00004028 | Brain and Centr... | carmustine conventional su... | 18 Years - | National Cancer Institute (NCI) | |
Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastoma | NCT04143425 | Adult Glioblast... Magnetic Resona... Bevacizimab | 3-Tesla convent... Advanced imagin... Dynamic suscept... | 18 Years - 80 Years | Asan Medical Center | |
Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma | NCT01730950 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Recurrent Adult... | bevacizumab radiation thera... | 18 Years - | Radiation Therapy Oncology Group | |
Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme | NCT00915694 | Brain and Centr... | nelfinavir mesy... temozolomide adjuvant therap... radiation thera... | 18 Years - 120 Years | Abramson Cancer Center at Penn Medicine |